Nonimmunogenetic Viral Capsid Carrier with Cancer Targeting Activity

Bo Ram Lee, Eunji Jo, Hong Yeol Yoon, Chul Joo Yoon, Hyo Jung Lee, Koo Chul Kwon, Tae Woo Kim, Jeewon Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Although protein nanoparticles (PNPs) (e.g., viral capsids) capable of delivering a broad range of drug agents have shown distinctive advantages over synthetic nanomaterials, PNPs have an intrinsic drawback that hampers their clinical application, that is, potential immunogenicity. Here, a novel method for resolving the immunogenicity problem of PNPs, which is based on the genetic presentation of albumin-binding peptides (ABPs) on the surface of PNP, is reported. ABPs are inserted into the surface of a viral capsid (hepatitis B virus capsid/HBVC) while preserving the native self-assembly function of HBVC. The ABPs effectively gather human serum albumins around HBVC and significantly reduce both inflammatory response and immunoglobulin titer in live mice compared to ABP-free HBVC. Furthermore, ABP-conjugated HBVCs remain within tumors for a longer period than HBVCs conjugated to tumor cell receptor-bindingpeptides, indicating that the ABPs are also capable of enhancing tumor-targeting performance. Although applied to HBVC for proof of concept, this novel approach may provide a general platform for resolving immunogenicity and cancer-targeting problems of PNPs, which enables the development of a variety of PNP-based drug delivery carriers with high safety and efficacy.

Original languageEnglish
Article number1800494
JournalAdvanced Science
Volume5
Issue number8
DOIs
Publication statusPublished - 2018 Aug 1

Fingerprint

Capsid
albumins
Nanoparticles
Peptides
Albumins
peptides
cancer
Proteins
proteins
nanoparticles
Tumors
Neoplasms
tumors
drugs
Drug Carriers
hepatitis
Nanostructures
Protein Transport
Drug delivery
Viruses

Keywords

  • albumin
  • albumin-binding peptides
  • immunogenicity
  • protein nanoparticles
  • tumor targeting
  • viral capsids

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Chemical Engineering(all)
  • Materials Science(all)
  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • Engineering(all)
  • Physics and Astronomy(all)

Cite this

Lee, B. R., Jo, E., Yoon, H. Y., Yoon, C. J., Lee, H. J., Kwon, K. C., ... Lee, J. (2018). Nonimmunogenetic Viral Capsid Carrier with Cancer Targeting Activity. Advanced Science, 5(8), [1800494]. https://doi.org/10.1002/advs.201800494

Nonimmunogenetic Viral Capsid Carrier with Cancer Targeting Activity. / Lee, Bo Ram; Jo, Eunji; Yoon, Hong Yeol; Yoon, Chul Joo; Lee, Hyo Jung; Kwon, Koo Chul; Kim, Tae Woo; Lee, Jeewon.

In: Advanced Science, Vol. 5, No. 8, 1800494, 01.08.2018.

Research output: Contribution to journalArticle

Lee BR, Jo E, Yoon HY, Yoon CJ, Lee HJ, Kwon KC et al. Nonimmunogenetic Viral Capsid Carrier with Cancer Targeting Activity. Advanced Science. 2018 Aug 1;5(8). 1800494. https://doi.org/10.1002/advs.201800494
Lee, Bo Ram ; Jo, Eunji ; Yoon, Hong Yeol ; Yoon, Chul Joo ; Lee, Hyo Jung ; Kwon, Koo Chul ; Kim, Tae Woo ; Lee, Jeewon. / Nonimmunogenetic Viral Capsid Carrier with Cancer Targeting Activity. In: Advanced Science. 2018 ; Vol. 5, No. 8.
@article{1fe25cada2fd470e945548e651704da6,
title = "Nonimmunogenetic Viral Capsid Carrier with Cancer Targeting Activity",
abstract = "Although protein nanoparticles (PNPs) (e.g., viral capsids) capable of delivering a broad range of drug agents have shown distinctive advantages over synthetic nanomaterials, PNPs have an intrinsic drawback that hampers their clinical application, that is, potential immunogenicity. Here, a novel method for resolving the immunogenicity problem of PNPs, which is based on the genetic presentation of albumin-binding peptides (ABPs) on the surface of PNP, is reported. ABPs are inserted into the surface of a viral capsid (hepatitis B virus capsid/HBVC) while preserving the native self-assembly function of HBVC. The ABPs effectively gather human serum albumins around HBVC and significantly reduce both inflammatory response and immunoglobulin titer in live mice compared to ABP-free HBVC. Furthermore, ABP-conjugated HBVCs remain within tumors for a longer period than HBVCs conjugated to tumor cell receptor-bindingpeptides, indicating that the ABPs are also capable of enhancing tumor-targeting performance. Although applied to HBVC for proof of concept, this novel approach may provide a general platform for resolving immunogenicity and cancer-targeting problems of PNPs, which enables the development of a variety of PNP-based drug delivery carriers with high safety and efficacy.",
keywords = "albumin, albumin-binding peptides, immunogenicity, protein nanoparticles, tumor targeting, viral capsids",
author = "Lee, {Bo Ram} and Eunji Jo and Yoon, {Hong Yeol} and Yoon, {Chul Joo} and Lee, {Hyo Jung} and Kwon, {Koo Chul} and Kim, {Tae Woo} and Jeewon Lee",
year = "2018",
month = "8",
day = "1",
doi = "10.1002/advs.201800494",
language = "English",
volume = "5",
journal = "Advanced Science",
issn = "2198-3844",
publisher = "Wiley-VCH Verlag",
number = "8",

}

TY - JOUR

T1 - Nonimmunogenetic Viral Capsid Carrier with Cancer Targeting Activity

AU - Lee, Bo Ram

AU - Jo, Eunji

AU - Yoon, Hong Yeol

AU - Yoon, Chul Joo

AU - Lee, Hyo Jung

AU - Kwon, Koo Chul

AU - Kim, Tae Woo

AU - Lee, Jeewon

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Although protein nanoparticles (PNPs) (e.g., viral capsids) capable of delivering a broad range of drug agents have shown distinctive advantages over synthetic nanomaterials, PNPs have an intrinsic drawback that hampers their clinical application, that is, potential immunogenicity. Here, a novel method for resolving the immunogenicity problem of PNPs, which is based on the genetic presentation of albumin-binding peptides (ABPs) on the surface of PNP, is reported. ABPs are inserted into the surface of a viral capsid (hepatitis B virus capsid/HBVC) while preserving the native self-assembly function of HBVC. The ABPs effectively gather human serum albumins around HBVC and significantly reduce both inflammatory response and immunoglobulin titer in live mice compared to ABP-free HBVC. Furthermore, ABP-conjugated HBVCs remain within tumors for a longer period than HBVCs conjugated to tumor cell receptor-bindingpeptides, indicating that the ABPs are also capable of enhancing tumor-targeting performance. Although applied to HBVC for proof of concept, this novel approach may provide a general platform for resolving immunogenicity and cancer-targeting problems of PNPs, which enables the development of a variety of PNP-based drug delivery carriers with high safety and efficacy.

AB - Although protein nanoparticles (PNPs) (e.g., viral capsids) capable of delivering a broad range of drug agents have shown distinctive advantages over synthetic nanomaterials, PNPs have an intrinsic drawback that hampers their clinical application, that is, potential immunogenicity. Here, a novel method for resolving the immunogenicity problem of PNPs, which is based on the genetic presentation of albumin-binding peptides (ABPs) on the surface of PNP, is reported. ABPs are inserted into the surface of a viral capsid (hepatitis B virus capsid/HBVC) while preserving the native self-assembly function of HBVC. The ABPs effectively gather human serum albumins around HBVC and significantly reduce both inflammatory response and immunoglobulin titer in live mice compared to ABP-free HBVC. Furthermore, ABP-conjugated HBVCs remain within tumors for a longer period than HBVCs conjugated to tumor cell receptor-bindingpeptides, indicating that the ABPs are also capable of enhancing tumor-targeting performance. Although applied to HBVC for proof of concept, this novel approach may provide a general platform for resolving immunogenicity and cancer-targeting problems of PNPs, which enables the development of a variety of PNP-based drug delivery carriers with high safety and efficacy.

KW - albumin

KW - albumin-binding peptides

KW - immunogenicity

KW - protein nanoparticles

KW - tumor targeting

KW - viral capsids

UR - http://www.scopus.com/inward/record.url?scp=85051562561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051562561&partnerID=8YFLogxK

U2 - 10.1002/advs.201800494

DO - 10.1002/advs.201800494

M3 - Article

AN - SCOPUS:85051562561

VL - 5

JO - Advanced Science

JF - Advanced Science

SN - 2198-3844

IS - 8

M1 - 1800494

ER -